How are new therapies evaluated for effectiveness?
The efficacy of new therapies is evaluated through various endpoints, including:
- Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive. - Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse. - Response Rate (RR): The percentage of patients whose cancer shrinks or disappears after treatment. - Quality of Life (QoL): The overall impact of the treatment on the patients' well-being and daily functioning.
These endpoints help determine whether a new therapy provides a significant benefit over existing treatments.
